论文信息 - Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer - 字舞流文

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

E. Winer | J. Baselga | T. Wilson | J. Ware | D. Juric | J. Infante | J. Sachdev | H. Parmar | A. Cervantes | C. Saura | I. Krop | Mafalda Oliveira | D. Richards | D. D. Hoff | Xuyang Lu | S. Sanabria | J. Hsu | M. Patel